Division of Urology, Department of Surgery, McGill University Health Centre, McGill University, Montreal, Quebec, Canada.
Urology. 2012 Oct;80(4):795-9. doi: 10.1016/j.urology.2012.04.062. Epub 2012 Jul 31.
To characterize a contemporary cohort of patients with heterozygous (TZ) cystinuria and compare them with a concurrent cohort of patients with homozygous (MZ) cystinuria.
A retrospective review of prospectively collected data was performed for 42 consecutive patients presenting with a positive cyanide-nitroprusside test from September 2009 to September 2011. Clinical data were collected, including the findings from a detailed metabolic stone workup that included two 24-hour urine collections with quantitative cystine. The patients were divided into 2 groups: those with TZ (30-400 mg/d) and those with MZ (>400 mg/d) cystinuria.
One patient was excluded because the cystine excretion was within the normal range (<30 mg/d), 35 (83.3%) and 6 (14.3%) had TZ and MZ cystinuria, respectively. Compared with those with TZ cystinuria, those with MZ cystinuria were significantly younger at the first stone episode (median 48 years, range 14-67, vs 17, range 6-44, P = .002), more were female (20% vs 66.7%; P = .03), and more patients had bilateral stones (8.6% vs 50%; P = .03). Finally, the patients with MZ cystinuria had more stone episodes than those with TZ cystinuria (3 vs 1; P = .04). From the detailed metabolic stone evaluation, the incidence of hyperuricemia was significantly greater in the MZ patients (17.1% vs 66.7%; P = .02). Although all the MZ patients developed pure cystine stones, 18 (51.4%), 7 (20.0%), and 3 (8.6%) of the TZ patients developed calcium oxalate, uric acid, and cystine stones, respectively (P < .001). In the TZ group, 11 patients (31.4%) had false-negative results on subsequent cyanide-nitroprusside testing.
Significant differences were found between the patients with TZ and MZ cystinuria in terms of age at the first stone episode, male/female ratio, incidence of hyperuricemia, and stone composition. The clinical significance remains to be elucidated.
描述一组杂合子(TZ)胱氨酸尿症患者的当代队列,并将其与一组同时期的纯合子(MZ)胱氨酸尿症患者进行比较。
对 2009 年 9 月至 2011 年 9 月期间进行的前瞻性收集数据进行回顾性分析,纳入 42 例氰化物-硝基普立司特试验阳性的连续就诊患者。收集临床数据,包括详细代谢性结石检查的结果,包括两次 24 小时尿液收集,进行定量胱氨酸检测。患者分为两组:TZ(30-400mg/d)组和 MZ(>400mg/d)胱氨酸尿症组。
排除 1 例因胱氨酸排泄量在正常范围内(<30mg/d)的患者,35 例(83.3%)和 6 例(14.3%)患者分别患有 TZ 和 MZ 胱氨酸尿症。与 TZ 胱氨酸尿症患者相比,MZ 胱氨酸尿症患者首次结石发作的年龄明显更小(中位数 48 岁,范围 14-67 岁,vs. 17 岁,范围 6-44 岁,P=.002),女性比例更高(20% vs. 66.7%,P=.03),双侧结石的比例更高(8.6% vs. 50%,P=.03)。此外,MZ 胱氨酸尿症患者的结石发作次数多于 TZ 胱氨酸尿症患者(3 次 vs. 1 次,P=.04)。从详细的代谢性结石评估来看,MZ 患者的高尿酸血症发生率明显更高(17.1% vs. 66.7%,P=.02)。尽管所有 MZ 患者均形成纯胱氨酸结石,但 18 例(51.4%)、7 例(20.0%)和 3 例(8.6%)TZ 患者分别形成草酸钙、尿酸和胱氨酸结石(P<.001)。在 TZ 组中,11 例(31.4%)患者随后的氰化物-硝基普立司特试验出现假阴性结果。
在首次结石发作年龄、男女比例、高尿酸血症发生率和结石成分方面,TZ 和 MZ 胱氨酸尿症患者存在显著差异。其临床意义尚待阐明。